The PURPOSE trials will evaluate the safety and efficacy of an investigational, twice-yearly injectable medicine, lenacapavir, to reduce the chance of getting ... Purpose 1 · Purpose 2 · Purpose 3 · Purpose 4

24 июл. 2024 г. · We evaluated the safety and efficacy of twice-yearly subcutaneous lenacapavir or daily oral F/TAF for HIV prevention in adolescent girls and young women.

20 июн. 2024 г. · The company's twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in ...

5 авг. 2024 г. · This factsheet provides a summary of the PURPOSE 1 phase III clinical trial of lenacapavir for PrEP and F/TAF for cisgender women taking place in South Africa ...

17 июл. 2024 г. · The interim results showed no cases of HIV infection among 2134 women given lenacapavir. Sixteen cases of HIV infection were reported among 1068 ...

26 сент. 2024 г. · LEN, an HIV-1 capsid inhibitor delivered by subcutaneous injection twice a year, was shown to be highly effective in preventing HIV among cisgender men, ...

PURPOSE 1, which enrolled cisgender women, will evaluate an investigational drug, lenacapavir, and an FDA-approved PrEP drug for people assigned male at birth.

20 сент. 2022 г. · The primary objective of this study is to evaluate the efficacy of lenacapavir (LEN) and emtricitabine/tenofovir alafenamide (F/TAF) in preventing the risk of ...

12 сент. 2024 г. · While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV at multiple stages of its lifecycle and ...

Lenacapavir is a drug that has been approved by the U.S. Food and Drug Administration (FDA) under the brand name Sunlenca for the treatment of HIV.